Radiopharm Theranostics Limited (RAD) Price & Analysis

Compare

17 Followers

RAD Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.05

Previous CloseN/A

Volume5.13M

Average Volume (3M)2.48M

Market Cap

AU$58.35M

Enterprise ValueAU$21.91M

Total Cash (Recent Filing)AU$36.44M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.28

Next Earnings

Sep 25, 2025

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding2,333,980,200

10 Day Avg. Volume3,710,435

30 Day Avg. Volume2,477,173

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)0.86

Price to Sales (P/S)0.00

P/FCF Ratio-1.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.05

Price Target Upside150.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Radiopharm Theranostics Limited News

PremiumThe Fly

Radiopharm announces dosing of first patient in Phase 1 HEAT trial

5d ago

RADX

PremiumThe Fly

Radiopharm reports preclinical Lu177-B7H3-mAb data

7d ago

RADX

PremiumThe Fly

Radiopharm pipeline ‘dramatically’ undervalued, says JonesResearch

18d ago

RADX

PremiumThe Fly

Radiopharm, ITM sign supply agreement for n.c.a. Lutetium-177

21d ago

RADX

PremiumThe Fly

Radiopharm says DSMC says Phase 1 study may continue as planned

28d ago

RADX

PremiumThe Fly

Radiopharm initiated with a Buy at ThinkEquity

28d ago

RADX

PremiumCompany Announcements

Radiopharm Theranostics Initiates Phase 1 Trial for Novel Cancer Treatment

6d ago

RAD

PremiumCompany Announcements

Radiopharm Theranostics Advances RV01 Program with Promising Preclinical Data

8d ago

RAD

See All AU:RAD News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe advancement of RAD 204 into a first-in-human Phase I trial in non-small cell lung cancer is a significant development for Radiopharm Theranostics.

Strategic FocusRadiopharm Theranostics focuses its therapeutic pipeline on biologically validated targets that have limited use in radiopharmaceuticals, reducing development risk and competition.

Bears Say

Capital RaiseThe AUD 70M capital raise resulted in higher dilution than previously estimated due to associated lower prices.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

8.26% Insiders

―

Mutual Funds

― Other Institutional Investors

91.74% Public Companies and

Individual Investors

Detailed Ownership Overview >

RAD FAQ

What was Radiopharm Theranostics Limited’s price range in the past 12 months?

Radiopharm Theranostics Limited lowest share price was AU$0.02 and its highest was AU$0.05 in the past 12 months.

What is Radiopharm Theranostics Limited’s market cap?

Radiopharm Theranostics Limited’s market cap is AU$58.35M.

When is Radiopharm Theranostics Limited’s upcoming earnings report date?

Radiopharm Theranostics Limited’s upcoming earnings report date is Sep 25, 2025 which is in 108 days.

How were Radiopharm Theranostics Limited’s earnings last quarter?

Radiopharm Theranostics Limited released its earnings results on Feb 28, 2025. The company reported -AU$0.01 earnings per share for the quarter, the consensus estimate of -AU$0.01 by AU$0.

Is Radiopharm Theranostics Limited overvalued?

According to Wall Street analysts Radiopharm Theranostics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Radiopharm Theranostics Limited pay dividends?

Radiopharm Theranostics Limited does not currently pay dividends.

What is Radiopharm Theranostics Limited’s EPS estimate?

Radiopharm Theranostics Limited’s EPS estimate is -0.01.

How many shares outstanding does Radiopharm Theranostics Limited have?

Radiopharm Theranostics Limited has 2,333,980,200 shares outstanding.

What happened to Radiopharm Theranostics Limited’s price movement after its last earnings report?

Radiopharm Theranostics Limited reported an EPS of -AU$0.01 in its last earnings report, expectations of -AU$0.01. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Radiopharm Theranostics Limited?

Currently, no hedge funds are holding shares in AU:RAD

Radiopharm Theranostics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-108.26%

Trailing 12-Months

Asset Growth

46.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Radiopharm Theranostics Limited

Radiopharm Theranostics Limited develops radiopharmaceutical products for diagnostic and therapeutic uses. The company was incorporated in 2021 and is based in Carlton, Australia.

RAD Stock 12 Month Forecast

Average Price Target

AU$0.05

▲(150.00%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2023","6":"Apr<br/>2023","9":"Jun<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.02230769230769231,0.024615384615384615,0.026923076923076925,0.029230769230769234,0.03153846153846154,0.033846153846153845,0.036153846153846154,0.038461538461538464,0.04076923076923077,0.04307692307692308,0.045384615384615384,0.0476923076923077,{"y":0.05,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.02230769230769231,0.024615384615384615,0.026923076923076925,0.029230769230769234,0.03153846153846154,0.033846153846153845,0.036153846153846154,0.038461538461538464,0.04076923076923077,0.04307692307692308,0.045384615384615384,0.0476923076923077,{"y":0.05,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.02230769230769231,0.024615384615384615,0.026923076923076925,0.029230769230769234,0.03153846153846154,0.033846153846153845,0.036153846153846154,0.038461538461538464,0.04076923076923077,0.04307692307692308,0.045384615384615384,0.0476923076923077,{"y":0.05,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.12,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.11,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.13,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.07,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >